Overview
Our technology platforms support key decision-making in:
- Early discovery and screening
- Candidate selection
- First-in-human translation and early development
- Late stage, multi-center determination of efficacy
Drug Discovery
Perceptive has a vast range of tools that help accelerate your drug discovery and development process.
Experience
We have experience working with a wide range of therapeutics, including small molecules, peptides, proteins, antibodies, multi-specific proteins, CAR-T cells, viruses, antisense oligonucleotides (ASO), DNA, RNA and others. Invicro strives to answer a wide array of biological questions, including but not limited to:
- Target identification
- Target density (Bmax)
- Binding affinity (KD)
- Target engagement
- Target occupancy, impact of dosing regimens, and route of administration
- Biodistribution and pharmacokinetics (ADME, DMPK)
- Pharmacodynamics (PD)
- Efficacy
Capabilities: In Vivo
Perceptive offers in vitro assays and in vivo imaging across resolutions and sensitivities. We design studies that combine different technologies spanning various platforms, including:
- IVIS Bioluminescence
- IVIS Fluorescence
- MRI
- PET
- SPECT
- CT
- Ultrasound
- AAALAC accredited facilities
- All Major Disease Areas
- All Major Tumor Models
- All Major Research Species
- Clinical Imaging
- Veterinary Radiology
Capabilities: Ex Vivo
- Cryo-fluorescence tomography (CFT)
- ex vivo fluorescence imaging
- Confocal microscopy
- Autoradiography & micro-autoradiography
- Homogenate radioligand binding assays
- Gamma counting and liquid scintillation
- Flow cytometry
- Clinical chemistry
- CBC Analysis
- Urinalysis
Capabilities: In Vitro and Chemistry
- Cell Culture
- Cell binding and competition
- Internalization
- Tissue homogenate binding
- Imaging agent radiolabeling
- Oligos to Antibodies
- Nanoparticles
- Viruses
- Cells
- Fluorescent labeling
Applications
Invicro leverages advanced tools to provide solutions to various questions in preclinical animal models (rodent to NHP) and in translational work in humans, including:
Biodistribution
- What is the in vivo distribution of a compound following intrathecal administration?
- Does a compound cross the BBB?
- What is the rate of clearance and route of elimination of a novel antisense oligonucleotide (ASO)?
- What is the fate of the cargo with respect to the carrier (e.g., for an antibody drug conjugate or a drug loaded liposome)?
- What is the integrity of a novel implant material over time?
- Does a novel alpha radiopharmaceutical exhibit tumor cell internalization in vivo?
- What is the fate and persistence of my therapeutic T cells?
- Where and for how long is my gene of interest delivered and expressed?
PD biomarkers and efficacy
- Does my anti-cancer therapeutic inhibit tumor growth in an orthotopic, transgenic, or metastatic tumor model?
- Can tumor accumulation of a novel radiolabeled compound predict treatment response?
- Are there synergistic effects when combining an alpha radiopharmaceutical with an immunotherapy agent?
- Does colon wall thickness in an animal model of IBD change following treatment?
- Does my anticancer therapeutic decrease tumor burden in my deep tissue tumor model?
- Does liver fat fraction or fibrosis stabilize or decrease with my treatment?
- Does my immune-modulator increase T cell activation in a tumor, and with what timing?
Target Validation/Engagement
- What is the receptor occupancy of a compound following oral dosing?
- Does my targeted biologic bind preferentially in a target expressing tumor vs. a target negative tumor?
- Does my novel drug delivery system (e.g. virus) reach its target in vivo
Safety
- What is the estimated human dosimetry (absorbed dose) for a novel radiotracer?
- Is there angiogenesis surrounding a surgical implant?
